This is a rare condition where the immune system grows too much, mainly in the lungs. It's caused by a virus changing B-cells in a T-cell rich area. It's similar to another type of lymphoma that affects the skin.
Every report comes from a Lived member, sent anonymously.
Have you tried Rituximab for Lymphomatoid Granulomatosis?
Lymphomatoid granulomatosis (LYG) is a rare disease in which B cells, a type of white blood cell, become infected with Epstein-Barr virus (EBV) and grow abnormally. These cells gather in tissues together with many inflammatory cells, clustering around and invading blood vessels, which can damage the vessels and cause areas of tissue to die. It sits between an inflammatory condition and a lymphoma (a cancer of the immune system), and in some people it behaves much like a lymphoma. LYG almost always affects the lungs, usually as nodules (rounded spots) in both lungs. It often reaches other organs too, especially the brain and nervous system, skin, liver and kidneys. Unlike most lymphomas, it rarely involves the lymph nodes, spleen or bone marrow. Common symptoms are cough, shortness of breath or chest pain, often with fever and weight loss. Without recognition and treatment, it can cause steadily worsening lung function, damage in the nervous system, or change into an aggressive EBV-positive lymphoma.
EBV is a very common virus that most adults have carried silently since an earlier infection. In LYG, the immune system appears to lose its normal control over EBV-infected B cells, so those cells can multiply. Most people with LYG have no known immune disorder, although testing often shows subtle problems with immune function. The disease is diagnosed more often in people whose immune systems are weakened, including people with HIV, people who have received an organ transplant and people with certain inherited immune deficiencies such as Wiskott-Aldrich syndrome. It is about twice as common in men as in women and is usually diagnosed between the ages of 30 and 60, although children and younger adults can be affected. There is no known way to prevent it.
Because LYG is rare and its symptoms are not specific, diagnosis is often delayed. Infections, inflammatory diseases that affect blood vessels and other lymphomas can all look similar. A CT scan of the chest usually shows nodules in both lungs, but imaging alone cannot tell LYG apart from these other conditions. The diagnosis needs a biopsy, a tissue sample examined by a pathologist, most often from the lung and sometimes from the skin or another affected organ. The pathologist looks for the typical pattern of cells around blood vessels and uses special stains to find EBV inside the abnormal B cells. A larger sample, or samples from more than one nodule, may be needed, because the disease can look different from one spot to another. The biopsy also sets the grade, which is the single most important result for treatment. Low grade (grades 1 and 2) means relatively few EBV-infected B cells. High grade (grade 3) means many large abnormal B cells and behaves like an aggressive lymphoma. Staging usually includes brain MRI and sometimes a spinal fluid sample, since the nervous system is often involved even without symptoms, along with blood tests.
Treatment depends mainly on the grade, and the evidence comes largely from a small number of patients treated at the US National Cancer Institute rather than from large comparative trials. For low-grade disease, the aim is to strengthen the body's own immune control of EBV. Interferon alfa-2b, a lab-made version of a natural immune signaling protein, is injected under the skin several times a week, and the dose is raised gradually until the disease responds. Treatment usually continues for about a year after the best response. In the main trial, most people treated this way had their disease disappear on scans, and about half remained free of progression five years later. Interferon often lowers blood counts, so regular blood tests are part of treatment. Low-grade disease occasionally improves without treatment, and a few people are carefully watched at first. High-grade disease is treated like aggressive lymphoma with immunochemotherapy: several chemotherapy drugs combined with rituximab, an antibody that targets B cells. One regimen used for LYG is DA-EPOCH-R, an abbreviation of its six drugs with doses adjusted to each person's blood counts, given in cycles every three weeks, usually six cycles. Most people respond, but low blood counts and infections are common, and the disease returns more often than with low-grade disease. Steroids or other medicines that suppress the immune system may shrink symptoms briefly but can let the disease worsen, so they are not used alone as treatment. For disease that does not respond or keeps returning, a stem cell transplant may be considered, though its benefit is not well established.
LYG is a serious disease, and outcomes vary widely. Some people reach a long remission after a single course of treatment, while others relapse and need more treatment. A distinctive feature is that the disease can change grade: high-grade disease can come back as low-grade disease after chemotherapy, and low-grade disease can turn high grade during interferon treatment. Because of this, a return or worsening of disease usually leads to a new biopsy so treatment can be switched to match the current grade, and switching often works. Treatment and follow-up take time. Interferon is often given for a year or more, and chemotherapy involves several months of cycles and frequent blood tests. During chemotherapy, infection risk is higher and fatigue can limit work and daily activity. After treatment, regular scans continue for years. Scars in the lungs may remain visible on CT even when the disease is in remission, so a follow-up scan is read alongside symptoms and earlier images rather than on its own.
See a doctor if a cough, shortness of breath or chest pain lasts for weeks, especially with fevers or weight loss you cannot explain, or if lung nodules found on a scan do not clear as expected after treatment for infection. If you have LYG, contact your care team promptly about breathing that is getting worse, new headaches, confusion, weakness, vision changes or other new nervous system symptoms, or new skin lumps or sores. These can signal that the disease is progressing or has spread. During chemotherapy, call your care team right away for a fever, as your team has instructed, because infections can become serious quickly when blood counts are low.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Lymphomatoid Granulomatosis is like, what's helped you, or ask the community a question.